Following the Appraisal Committee meeting on Lenalidomide for multiple myeloma after 1 prior treatment with bortezomib [ID667] in March 2017, we have suspended this appraisal.
From discussions with the company we understand that it is considering alternative access options for lenalidomide, which means that the basis for the decision making is likely to change. NICE is committed to working towards a solution that ensures patients with multiple myeloma continue to have access to lenalidomide. We therefore do not consider it appropriate to release an FAD at this stage. We will provide an update on the future timelines as soon as we can.